Trial Watch: Dendritic cell-based interventions for cancer therapy

Erika Vacchelli, Ilio Vitale, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fučíková, Isabelle Cremer, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

146 Citaten (Scopus)

Samenvatting

Dendritic cells (DCs) occupy a privileged position at the interface between innate and adaptive immunity, orchestrating a large panel of responses to both physiological and pathological cues. In particular, whereas the presentation of antigens by immature DCs generally results in the development of immunological tolerance, mature DCs are capable of priming robust, and hence therapeutically relevant, adaptive immune responses. In line with this notion, functional defects in the DC compartment have been shown to etiologically contribute to pathological conditions including (but perhaps not limited to) infectious diseases, allergic and autoimmune disorders, graft rejection and cancer. Thus, the possibility of harnessing the elevated immunological potential of DCs for anticancer therapy has attracted considerable interest from both researchers and clinicians over the last decade. Alongside, several methods have been developed not only to isolate DCs from cancer patients, expand them, load them with tumorassociated antigens and hence generate highly immunogenic clinical grade infusion products, but also to directly target DCs in vivo. This intense experimental effort has culminated in 2010 with the approval by the US FDA of a DC-based preparation (sipuleucel-T, Provenge®) for the treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer. As an update to the latest Trial Watch dealing with this exciting field of research (October 2012), here we summarize recent advances in DC-based anticancer regimens, covering both high-impact studies that have been published during the last 13 mo and clinical trials that have been launched in the same period to assess the antineoplastic potential of this variant of cellular immunotherapy

Originele taal-2Engels
Artikelnummere25771
TijdschriftOncoImmunology
Volume2
Nummer van het tijdschrift10
DOI's
StatusGepubliceerd - 2013
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Trial Watch: Dendritic cell-based interventions for cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit